SCHEMBL1259532

SCHEMBL1259532

O=[N+]([O-])c1ccccc1O[PH](=O)O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.59
NPC1 O15118 2/20 0.59
RECQL P46063 1/20 0.59
ALDH1A1 P00352 6/20 0.56
TDP1 Q9NUW8 2/20 0.56
KMT2A Q03164 4/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 1/20 0.51
L3MBTL1 Q9Y468 3/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 2/20 0.46
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
ESR2 Q92731 1/20 0.44
GPR35 Q9HC97 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1259536 1.00 RAB9A (0.59) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL1259531 0.85 ALDH1A1 (0.60) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL176880 0.83 TDP1 (0.56) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL176878 0.83 TDP1 (0.56) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL8456522 0.77 ALDH1A1 (0.51) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL7922499 0.76 ALDH1A1 (0.64) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL39472 0.76 HPGD (0.78) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL10728673 0.76 ALDH1A1 (0.58) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL9187561 0.75 NPC1 (1.00) RAB9ANPC1RECQLALDH1A1TDP1
SCHEMBL26509809 0.74 ALDH1A1 (0.67) RAB9ANPC1RECQLALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024025604-A9 DEVELOPMENT OF AN ENZYME-INHIBITOR REACTION USING CELLULAR RETINOIC ACID BINDING PROTEIN II FOR ONE-POT MEGAMOLECULE ASSEMBLY NORTHWESTERN UNIVERSITY (US) 2024-05-02 WO claimed
WO-2024025604-A2 DEVELOPMENT OF AN ENZYME-INHIBITOR REACTION USING CELLULAR RETINOIC ACID BINDING PROTEIN II FOR ONE-POT MEGAMOLECULE ASSEMBLY NORTHWESTERN UNIVERSITY (US) 2024-02-01 WO claimed
EP-3464384-A1 FUSION PROTEIN CONSTRUCT Northwestern University (US) 2019-04-10 EP claimed
WO-2017214151-A1 FUSION PROTEIN CONSTRUCT NORTHWESTERN UNIVERSITY (US) 2017-12-14 WO claimed
US-20250326723-A1 Development of an Enzyme-Inhibitor Reaction Using Cellular Retinoic Acid Binding Protein II for One-Pot Megamolecule Assembly UNIV NORTHWESTERN (US) 2025-10-23 US disclosed
WO-2024025604-A9 DEVELOPMENT OF AN ENZYME-INHIBITOR REACTION USING CELLULAR RETINOIC ACID BINDING PROTEIN II FOR ONE-POT MEGAMOLECULE ASSEMBLY NORTHWESTERN UNIVERSITY (US) 2024-05-02 WO disclosed
WO-2024025604-A2 DEVELOPMENT OF AN ENZYME-INHIBITOR REACTION USING CELLULAR RETINOIC ACID BINDING PROTEIN II FOR ONE-POT MEGAMOLECULE ASSEMBLY NORTHWESTERN UNIVERSITY (US) 2024-02-01 WO disclosed
US-11667648-B2 Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements PROMEGA CORPORATION (US) 2023-06-06 US disclosed
CN-112996497-A Morphic forms of complement factor D inhibitors 艾其林医药公司 2021-06-18 CN disclosed
WO-2021056811-A1 IMINE SALT DERIVATIVE AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR NICOTINE 深圳黑尔格科技有限公司 2021-04-01 WO disclosed
US-20200199140-A1 CELL-PERMEABLE, CELL-COMPATIBLE, AND CLEAVABLE LINKERS FOR COVALENT TETHERING OF FUNCTIONAL ELEMENTS PROMEGA CORPORATION 2020-06-25 US disclosed
US-10618907-B2 Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements PROMEGA CORPORATION (US) 2020-04-14 US disclosed
US-20030119054-A1 Polypeptide immobilization NATIONAL SCIENCE FOUNDATION 2003-06-26 US disclosed
EP-0946755-A4 METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING MAXYGEN INC (US) 2001-03-07 EP disclosed
EP-0946755-A1 METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING Maxygen, Inc. (US) 1999-10-06 EP disclosed
WO-1998027230-A1 METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING MAXYGEN, INC. (US) 1998-06-25 WO disclosed
EP-0362304-B1 CHEMICAL SENSORS EMPLOYING CATALYTIC ANTIBODIES IGEN INC (US) 1997-03-05 EP disclosed
EP-0362304-A4 CHEMICAL SENSORS EMPLOYING CATALYTIC ANTIBODIES 1991-04-10 EP disclosed
EP-0362304-A1 CHEMICAL SENSORS EMPLOYING CATALYTIC ANTIBODIES. IGEN INC (US) 1990-04-11 EP disclosed
WO-1989005977-A1 CHEMICAL SENSORS EMPLOYING CATALYTIC ANTIBODIES IGEN, INC. (US) 1989-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199140-A1 CELL-PERMEABLE, CELL-COMPATIBLE, AND CLEAVABLE LINKERS FOR COVALENT TETHERING OF FUNCTIONAL ELEMENTS LNPK, EPCAM, AFG3L2 RAB9A 1949/4885NPC1 1091/4885RECQL 3094/4885
US-20030119054-A1 Polypeptide immobilization SURF4, QPCTL, QPCT RAB9A 4710/4885NPC1 3727/4885RECQL 3512/4885
US-11667648-B2 Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements LNPK, EPCAM, AFG3L2 RAB9A 1949/4885NPC1 1091/4885RECQL 3094/4885
US-10618907-B2 Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements LNPK, EPCAM, AFG3L2 RAB9A 1949/4885NPC1 1091/4885RECQL 3094/4885
US-20250326723-A1 Development of an Enzyme-Inhibitor Reaction Using Cellular Retinoic Acid Binding Protein II for One-Pot Megamolecule Assembly CRABP2, RARB, RARA RAB9A 1966/4885NPC1 3855/4885RECQL 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.